transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.

Författare och institution:
Hugo Vanderstichele (-); Karen De Vreese (-); Kaj Blennow (Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi); Niels Andreasen (-); Christian Sindic (-); Adrian Ivanoiu (-); Harald Hampel (-); Katharina Bürger (-); Lucilla Parnetti (-); Alessia Lanari (-); Allesandro Padovani (-); Monica DiLuca (-); Miriam Bläser (-); Annika Öhrfelt Olsson (Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi); Hans Pottel (-); Frank Hulstaert (-); Eugeen Vanmechelen (-)
Publicerad i:
Clinical chemistry and laboratory medicine : CCLM / FESCC, 44 ( 12 ) s. 1472-80
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
BACKGROUND: Total tau (T-tau) and beta-amyloid((1-42)) (Abeta(1-42)) levels in cerebrospinal fluid (CSF) can differentiate Alzheimer's disease (AD) from normal aging or depressive pseudo-dementia. Differential diagnosis from dementia with Lewy bodies (DLB) in clinical settings is difficult. METHODS: The analytical performance of the INNOTEST PHOSPHO-TAU(181P) assay was validated in terms of selectivity, sensitivity, specificity, precision, robustness, and stability. Clinical utility of the assay alone, or combined with T-tau and Abeta(1-42), for discrimination of AD (n=94) from patients suffering from DLB (n=60) or from age-matched control subjects (CS) (n=60) was assessed in a multicenter study. RESULTS: CSF concentrations of tau phosphorylated at threonine 181 (P-tau(181P)) in AD was significantly higher than in DLB and CS. Discriminant analysis, a classification tree, and logistic regression showed that P-tau(181P) was the most statistically significant single variable of the three biomarkers for discrimination between AD and DLB. CONCLUSIONS: P-tau(181P) quantification is a robust and reliable assay that may be useful in discriminating AD from DLB.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Medicinska grundvetenskaper ->
Neurovetenskaper ->
Aged, Alzheimer Disease, diagnosis, Amyloid beta-Protein, cerebrospinal fluid, Biological Markers, cerebrospinal fluid, Diagnosis, Differential, Discriminant Analysis, Enzyme-Linked Immunosorbent Assay, methods, Female, Humans, Lewy Body Disease, diagnosis, Logistic Models, Male, Middle Aged, Peptide Fragments, cerebrospinal fluid, Phosphothreonine, metabolism, ROC Curve, Reagent Kits, Diagnostic, standards, Reproducibility of Results, Sensitivity and Specificity, tau Proteins, cerebrospinal fluid, metabolism
Postens nummer:
Posten skapad:
2007-10-26 15:50
Posten ändrad:
2009-10-02 14:07

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007